The influence of two-way referral model on treatment and prognosis of patients with chronic heart failure
10.3760/cma.j.cn112148-20241216-00787
- VernacularTitle:双向转诊模式对慢性心力衰竭患者治疗和预后的影响
- Author:
Yijun SUN
1
;
Xinyu ZHANG
;
Yue HU
;
Zongwei LIN
;
Jie XIAO
;
Peng LI
;
Xin ZHAO
;
Huafang ZHANG
;
Bo QIN
;
Dequan JIA
;
Tao ZHANG
;
Jian MA
;
Hongping CHEN
;
Chunju ZHANG
;
Xinwei GENG
;
Kaiyan ZHANG
;
Man ZHENG
;
Fenglei ZHANG
;
Yan LANG
;
Hegong HOU
;
Peng LIU
;
Haifeng JIA
;
Jianjun LU
;
Kai ZHAO
;
Hui ZHAO
;
Jiechang XU
;
Mi ZHANG
;
Xiuxin LI
;
Dongxia ZHANG
;
Lin ZHONG
;
Hui ZHAO
;
Fangfang LIU
;
Yan LIU
;
Dongxia MIAO
;
Chengwei WANG
;
Hui ZHANG
;
Chen WANG
;
Fen WANG
;
Xuejuan ZHANG
;
Huixia LYU
;
Xiaoping JI
Author Information
1. 山东大学齐鲁医院心内科，济南 250012
- Publication Type:Journal Article
- Keywords:
Heart failure;
Two-way referral model;
Patient management
- From:
Chinese Journal of Cardiology
2025;53(11):1244-1253
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the impact of the two-way referral model on compliance and prognosis in patients with heart failure.Methods:This bidirectional cohort study enrolled chronic heart failure (CHF) patients treated at Qilu Hospital of Shandong University or designated primary hospitals between March 2018 and March 2022. Patients were categorized into two groups based on referral status: two-way referral group (participating in the referral model with≥1 follow-up visit at primary hospitals) and the core hospital group (receiving treatment and follow-up exclusively at Qilu Hospital). Baseline clinical characteristics were collected and compared between groups. Patients underwent followed-up, with primary endpoints including follow-up rate, drug (β-blockers, angiotension converting enzyme inhibitor (ACEI)/angiotensin Ⅱ receptor blockers (ARB)/angiotensin receptor-neprilysin inhibitor (ARNI), sodium-glucose cotransporter 2 inhibitors and mineralocorticoid receptor antagonists) utilization rate and target dose achievement rate. Secondary endpoints encompassed changes from baseline in left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDd), and N-terminal pro-brain natriuretic peptide (NT-proBNP), plus cardiovascular mortality and heart failure rehospitalization. Generalized linear mixed models analyzed longitudinal trends in LVEF, LVEDd, and NT-proBNP levels. Kaplan-Meier curves and Cox regression evaluated LVEF recovery rates, supplemented by subgroup analyses. Multivariate logistic regression was used to identify factors influencing target dose achievement rate for β-blockers and ACEI/ARB/ARNI therapies in CHF patients.Results:A total of 357 patients were enrolled, aged 53 (41, 63) years, including 256 males (71.7%). 157 patients were in the two-way referral group and 200 patients in the core hospital-treated group. Compared with the core hospital-treated group, the two-way referral group had lower baseline LVEF (28 (22, 34)% vs. 31 (23, 36)%, P=0.021) and systolic blood pressure (116 (104, 125) mmHg vs. 121 (109, 134) mmHg (1 mmHg=0.133 kPa), P=0.010). The 12-month follow-up rate of the two-way referral group was higher than the core hospital-treated group (73.8% vs. 56.0%, P=0.004). No significant between-group differences were observed in drug utilization rate of β-blockers, ACEI/ARB/ARNI, or sodium-glucose cotransporter 2 inhibitors during follow-up (all P>0.05), while mineralocorticoid receptor antagonists use showed a declining trend in both groups. Although the core hospital-treated group had higher target dose achievement rates for β-blockers (65.4% vs. 49.3%, P=0.042) and ACEI/ARB/ARNI (79.8% vs. 65.8%, P=0.046) than the two-way referral group, multivariate logistic regression indicated that the two-way referral model was not a negative predictor for these outcomes (all P>0.05). Both groups showed improved NT-proBNP, LVEDd, and LVEF from baseline (all P<0.001) with no significant difference in trends between groups (all P>0.05). There was no significant difference in the composite incidence (7.6% vs. 6.5%, P=0.674) and cumulative incidence (log-rank P=0.684) of cardiovascular death and heart failure rehospitalization at 12 months between two groups. Conclusion:The two-way referral model demonstrates advantages in improving medication adherence, drug utilization rates, and targetdoseachievement rates among CHF patients. This model not only promotes cardiac functional recovery but also reduces risks of cardiovascular mortality and heart failure rehospitalization, achieving comparable therapeutic and management outcomes to those observed in core hospital-treated patients.
